NCT06308926View on ClinicalTrials.gov

MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

February 1, 2026

Study Completion Date

July 1, 2026

Conditions
Acute Respiratory Distress SyndromeRespiratory FailureRespiratory Distress SyndromeRespiratory Tract DiseasesCytokine Storm
Interventions
DRUG

MRG-001 (Low-dose)

MRG-001 is subcutaneously administered.

DRUG

MRG-001 (High-dose)

MRG-001 is subcutaneously administered.

OTHER

Placebo

Saline placebo will be administered subcutaneously based on bodyweight and similar dose as the treatment group.

Sponsors

Lead Sponsor

MedRegen LLC
All Listed Sponsors
collaborator

Vanderbilt University Medical Center

OTHER

lead

MedRegen LLC

INDUSTRY

NCT06308926 - MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients | Biotech Hunter | Biotech Hunter